Capital Advisors Inc. OK Grows Stock Position in Medtronic PLC $MDT

Capital Advisors Inc. OK increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 4.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 472,638 shares of the medical technology company’s stock after acquiring an additional 19,180 shares during the period. Capital Advisors Inc. OK’s holdings in Medtronic were worth $41,200,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. 1248 Management LLC acquired a new stake in shares of Medtronic during the 1st quarter valued at about $26,000. Columbia River Financial Group LLC acquired a new stake in shares of Medtronic during the 1st quarter valued at about $28,000. Twin Tree Management LP acquired a new stake in shares of Medtronic during the 1st quarter valued at about $29,000. Activest Wealth Management grew its position in shares of Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares during the period. Finally, Hughes Financial Services LLC acquired a new stake in shares of Medtronic during the 1st quarter valued at about $32,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MDT has been the topic of a number of analyst reports. The Goldman Sachs Group dropped their target price on Medtronic from $82.00 to $81.00 and set a “sell” rating on the stock in a research report on Wednesday, October 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a report on Saturday, September 27th. Daiwa Capital Markets lifted their price objective on Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a report on Friday. Finally, Argus lifted their price objective on Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, August 26th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.94.

Medtronic Trading Up 2.3%

MDT opened at $97.63 on Monday. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The company’s 50 day simple moving average is $92.94 and its two-hundred day simple moving average is $88.46. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $97.94. The firm has a market capitalization of $125.23 billion, a price-to-earnings ratio of 26.90, a price-to-earnings-growth ratio of 2.57 and a beta of 0.78.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business had revenue of $8.58 billion for the quarter, compared to analyst estimates of $8.37 billion. During the same period last year, the company posted $1.23 EPS. The business’s revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is 78.24%.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William R. Jellison purchased 2,500 shares of Medtronic stock in a transaction dated Monday, August 25th. The shares were purchased at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the transaction, the director owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their position. The disclosure for this purchase can be found here. 0.26% of the stock is currently owned by insiders.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.